Photodynamic Therapy Market Size, Trend, Forecast Report 2026 to 2035

What is Photodynamic Therapy Market Size?

Global Photodynamic Therapy Market Size is valued at USD 655.71 Mn in 2025 and is predicted to reach USD 1,428.02 Bn by the year 2035 at a 8.4% CAGR during the forecast period for 2026 to 2035.

Photodynamic Therapy Market Size, Share & Trends Analysis Distribution By Target Indication (Actinic Keratosis, Prostate Cancer, Age-related Macular Degeneration, Head and Neck Squamous Cell Carcinoma, Basal Cell Carcinoma, Port Wine Stain, Barrett’s Esophagus, Esophageal Cancer, Endobronchial Cancer, Lung Cancer, Bowen’s Disease, Brain Cancer, Bladder Cancer, T-cell Lymphoma, Urothelial Cancer), By Therapeutic Area (Oncological Disorders, Dermatological Disorders, Ophthalmic Disorders) and Segment Forecasts, 2026 to 2035.

Photodynamic therapy (PDT) is attracting considerable interest owing to growing adoption of minimally invasive techniques for treating various forms of cancers, skin diseases, and eye diseases by healthcare institutions. The procedure entails the use of a photosensitizer drug together with a source of light that kills disease-causing cells without harming healthy tissue. As a result, it has been seen as a solution to managing such medical conditions as actinic keratosis, basal cell carcinoma, cancers of the head and neck, Barrett’s esophagus, bladder cancer, age-related macular degeneration, and others. As healthcare institutions strive to improve their patients’ well-being while minimizing side effects, more applications of PDT can be anticipated going forward. Among the factors that could contribute to the expansion of the market is the growing incidence of cancer and chronic skin conditions around the world. Increased emphasis on the need for early diagnosis and treatment, combined with a greater inclination towards adopting non-invasive approaches in therapy, is spurring the use of photodynamic therapy. In comparison to traditional methods of treatment like surgery, chemotherapy, and radiation therapy, PDT has several benefits, including minimal scarring, quick recovery time, possibility of re-treatment, and better quality of life.

Further advances in technology are also driving market growth. There are investments in the creation of the next generation photosensitizers, more effective light delivery systems, lasers, fiber optics, and imaging guided treatment systems that increase the effectiveness of treatments. Scientists are studying novel photosensitizers that will offer higher selectivity towards tumors, greater depth of tissue penetration and fewer adverse effects. This is extending the list of possible applications of photodynamic therapy. An important driver of growth will be research and development activity. Clinical trials are being conducted by pharmaceutical and biotechnology companies and hospitals to study the use of PDT for treating cancers and other diseases. There are collaborations between pharmaceutical companies, medical device companies and research organizations that are fostering innovation.

In spite of its bright prospects, this sector will be confronted with certain obstacles. Photodynamic therapy's efficiency can be affected by various issues including penetration depth of the light source, position of the tumor, photosensitive responses, and complication of treatment procedure, among others. Equipment and healthcare specialists trained in conducting such therapies are necessary for effective and safe delivery of PDT, which is another issue affecting widespread introduction of photodynamic therapy in healthcare. In addition, there is a number of other factors such as reimbursement rates, regulations and costs that may hinder more extensive market penetration. However, the market's long-term outlook is expected to be very bright. Growing number of patients with oncological diseases, increasing tendency toward minimally invasive procedures, innovative developments in technology and expanding scope of application areas are likely to continue boosting photodynamic therapy market development in the future.

Competitive Landscape

Which are the Leading Players in the Photodynamic Therapy Market?

• ADVANZ PHARMA
• Biofrontera
• biolitec Pharma
• Luzitin
• Nanospectra Biosciences
• photoatomic
• Rakuten Medical
• Impact Biotech
• Theralase
• Cetuximab Sarotalocan
• Alacare
• Ameluz
• Aminolevulinic Acid
• Foscan (Temoporfin)
• FuMeiDa (Hemoporfin)
• Levulan Kerastick
• Metvixia (Metvix)
• Photofrin
• Verteporfin (Visudyne)

Market Dynamics

Driver

Rising Demand for Minimally Invasive Cancer and Dermatology Treatments

One of the main factors that drives the growth of photodynamic therapy (PDT) market includes the rising trend towards minimally invasive treatment methods. Both doctors and patients prefer treatments that are effective in providing disease management, while being minimally damaging to the patient’s healthy tissues and allowing faster recovery and better outcomes for their health. Due to the mechanism of action and safety of PDT, it becomes increasingly popular as a means of treating different types of cancer, skin diseases, and ophthalmic diseases. The increasing incidences of diseases like actinic keratosis, basal cell carcinoma, head and neck cancer, bladder cancer, Barrett’s esophagus, and age-related macular degeneration also support the development of the market. Moreover, improvements made in photosensitizers, lasers, and light delivery devices increase the effectiveness of the procedure and allow using it for new indications.

Restrain/Challenge

Limited Treatment Penetration and Specialized Infrastructure Requirements

While PDT does have its clinical advantages, there are a number of difficulties associated with it that are likely to impede widespread uptake of the modality. Among these, the need for specialized equipment, expertise, and specific treatment methodologies stands out as one of the most important. The success of photodynamic therapy depends not only on the use of an appropriate photosensitizer but also on effective control over treatment procedures. Moreover, in some cases, the efficiency of photodynamic therapy might depend on specific features of lesions, including their depth and location, as well as the overall characteristics of individual patients. Finally, in some cases, photosensitivity reactions may occur as a side effect of treatment and thus require additional attention on the part of patients and clinicians.

Actinic Keratosis Segment is Expected to Drive the Photodynamic Therapy Market

The segment of actinic keratosis is anticipated to provide a significant boost to the photodynamic therapy market due to the rising cases of skin damage caused by the sun and the prevalence of pre-cancerous skin lesions across the globe. The adoption of photodynamic therapy for treating actinic keratosis is rising because this treatment helps in targeting several lesions with outstanding aesthetic results when compared with traditional modes of treatment. An increase in the prevalence of skin cancer, increased visits to dermatologists, and a growing preference for less invasive treatment alternatives are some factors driving the growth of this market segment.

Oncological Disorders Segment is Expected to Drive the Photodynamic Therapy Market

The oncological disorders segment is projected to contribute substantially to the total photodynamic therapy market as research on the effectiveness of PDT in oncology continues. Photodynamic therapy has started being used in treating head and neck squamous cell carcinoma, esophageal cancer, endobronchial cancer, lung cancer, bladder cancer, brain cancer, T-cell lymphoma, and urothelial cancer. The selective elimination of tumor cells and preservation of nearby healthy cells makes PDT a preferable treatment choice, especially when surgery is not an option. Clinical studies, increased regulatory approvals, and investment in innovation within oncology are likely to fuel the development of the oncological disorders segment over the forecast period.

Why North America Leads the Photodynamic Therapy Market?

North America leads the photodynamic therapy market due to its advanced healthcare infrastructure, strong oncology and dermatology treatment landscape, and significant investment in medical innovation. The region is home to numerous pharmaceutical companies, biotechnology firms, medical device manufacturers, and research institutions actively involved in developing and commercializing photodynamic therapy products. High awareness of cancer screening and skin disease management, favorable reimbursement frameworks, and strong clinical research activity continue to support market growth.

The United States, in particular, has witnessed increasing adoption of PDT for dermatological, oncological, and ophthalmic applications, supported by the availability of advanced treatment technologies and skilled healthcare professionals. In addition, ongoing research into next-generation photosensitizers and targeted light delivery systems is further strengthening the region's market position. With its robust healthcare ecosystem and continued investment in innovative treatment approaches, North America is expected to maintain its leadership in the global photodynamic therapy market.

Key Developments-

•    In March 2025, Rakuten Medical continued advancing the commercialization and clinical expansion of its photoimmunotherapy platform based on Cetuximab Sarotalocan, strengthening its presence in targeted cancer treatment and expanding research activities across multiple oncology indications.

•    In January 2025, Biofrontera reported ongoing efforts to expand the clinical adoption of its photodynamic therapy portfolio, including Ameluz®, through increased physician outreach, market expansion initiatives, and continued development of dermatological treatment applications.

Photodynamic Therapy Market Report Scope: